Vertex reaches CF deal in Scotland

After more than three years of negotiations, Vertex and Scotland have agreed to a five-year reimbursement agreement that gives cystic fibrosis patients access to two CF drugs, making Scotland the first in the U.K. to expand access to the drugs to all eligible patients.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) announced Thursday that it reached a deal with the Scottish government to provide access to Orkambi ivacaftor/lumacaftor and Symkevi tezacaftor/ivacaftor for an undisclosed discount. Of the 900 CF patients in Scotland, about 400 are eligible for the two drugs...